AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective

Journal of Medicinal Chemistry

Volumn 59, Issue 8, 2016, Pages 3593-3608

  Myers, Samuel H ^a   Brunton, Valerie G ^a   Unciti Broceta, Asier ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXL INHIBITOR; GROWTH ARREST SPECIFIC PROTEIN 6; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL AGGREGATION; CELL PROLIFERATION; DISEASE ASSOCIATION; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; MEDICINAL CHEMISTRY; NEOPLASM;

CHEMISTRY, PHARMACEUTICAL; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84966731058     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01273     Document Type: Review

References (115)

1. Robinson, D. R.; Wu, Y. M.; Lin, S. F. The protein tyrosine kinase family of the human genome Oncogene 2000, 19, 5548-5557 10.1038/sj.onc.1203957
2. Ségaliny, A. I.; Tellez-Gabriel, M.; Heymann, M.-F.; Heymann, D. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers J. Bone Oncol. 2015, 4, 1-12 10.1016/j.jbo.2015.01.001
3. O'Bryan, J. P.; Frye, R. A.; Cogswell, P. C.; Neubauer, A.; Kitch, B.; Prokop, C.; Espinosa, R.; Le Beau, M. M.; Earp, H. S.; Liu, E. T. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase Mol. Cell. Biol. 1991, 11, 5016-5031 10.1128/MCB.11.10.5016
4. Hutterer, M.; Knyazev, P.; Abate, A.; Reschke, M.; Maier, H.; Stefanova, N.; Knyazeva, T.; Barbieri, V.; Reindl, M.; Muigg, A.; Kostron, H.; Stockhammer, G.; Ullrich, A. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme Clin. Cancer Res. 2008, 14, 130-138 10.1158/1078-0432.CCR-07-0862
5. Wang, X.; Saso, H.; Iwamoto, T.; Xia, W.; Gong, Y.; Pusztai, L.; Woodward, W. A.; Reuben, J. M.; Warner, S. L.; Bearss, D. J.; Hortobagyi, G. N.; Hung, M. C.; Ueno, N. T. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase Cancer Res. 2013, 73, 6516-6525 10.1158/0008-5472.CAN-13-0967
6. Niederst, M. J.; Engelman, J. A. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer Sci. Signaling 2013, 6, re6 10.1126/scisignal.2004652
7. Han, J.; Tian, R.; Yong, B.; Luo, C.; Tan, P.; Shen, J.; Peng, T. Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients Biochem. Biophys. Res. Commun. 2013, 435, 493-500 10.1016/j.bbrc.2013.05.019
8. Ben-Batalla, I.; Schultze, A.; Wroblewski, M.; Erdmann, R.; Heuser, M.; Waizenegger, J. S.; Riecken, K.; Binder, M.; Schewe, D.; Sawall, S.; Witke, V.; Cubas-Cordova, M.; Janning, M.; Wellbrock, J.; Fehse, B.; Hagel, C.; Krauter, J.; Ganser, A.; Lorens, J. B.; Fiedler, W.; Carmeliet, P.; Pantel, K.; Bokemeyer, C.; Loges, S. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma Blood 2013, 122, 2443-2452 10.1182/blood-2013-03-491431
9. Byers, L. A.; Diao, L.; Wang, J.; Saintigny, P.; Girard, L.; Peyton, M.; Shen, L.; Fan, Y.; Giri, U.; Tumula, P. K.; Nilsson, M. B.; Gudikote, J.; Tran, H.; Cardnell, R. J.; Bearss, D. J.; Warner, S. L.; Foulks, J. M.; Kanner, S. B.; Gandhi, V.; Krett, N.; Rosen, S. T.; Kim, E. S.; Herbst, R. S.; Blumenschein, G. R.; Lee, J. J.; Lippman, S. M.; Ang, K. K.; Mills, G. B.; Hong, W. K.; Weinstein, J. N.; Wistuba, I. I.; Coombes, K. R.; Minna, J. D.; Heymach, J. V. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance Clin. Cancer Res. 2013, 19, 279-290 10.1158/1078-0432.CCR-12-1558
10. Cichoń, M. A.; Szentpetery, Z.; Caley, M. P.; Papadakis, E. S.; Mackenzie, I. C.; Brennan, C. H.; O'Toole, E. A. The receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous squamous cell carcinoma Oncogene 2014, 33, 4185-4192 10.1038/onc.2013.388
11. Zhang, Z.; Lee, J. C.; Lin, L.; Olivas, V.; Au, V.; LaFramboise, T.; Abdel-Rahman, M.; Wang, X.; Levine, A. D.; Rho, J. K.; Choi, Y. J.; Choi, C. M.; Kim, S. W.; Jang, S. J.; Park, Y. S.; Kim, W. S.; Lee, D. H.; Lee, J. S.; Miller, V. A.; Arcila, M.; Ladanyi, M.; Moonsamy, P.; Sawyers, C.; Boggon, T. J.; Ma, P. C.; Costa, C.; Taron, M.; Rosell, R.; Halmos, B.; Bivona, T. G. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Nat. Genet. 2012, 44, 852-860 10.1038/ng.2330
12. Brand, T. M.; Iida, M.; Stein, A. P.; Corrigan, K. L.; Braverman, C. M.; Luthar, N.; Toulany, M.; Gill, P. S.; Salgia, R.; Kimple, R. J.; Wheeler, D. L. AXL mediates resistance to cetuximab therapy Cancer Res. 2014, 74, 5152-5164 10.1158/0008-5472.CAN-14-0294
13. Hong, J.; Peng, D.; Chen, Z.; Sehdev, V.; Belkhiri, A. ABL regulation by AXL promotes cisplatin resistance in oesophageal cancer Cancer Res. 2013, 73, 331-340 10.1158/0008-5472.CAN-12-3151
14. Hong, C. C.; Lay, J. D.; Huang, J. S.; Cheng, A. L.; Tang, J. L.; Lin, M. T.; Lai, G. M.; Chuang, S. E. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia Cancer Lett. 2008, 268, 314-324 10.1016/j.canlet.2008.04.017
15. Sheridan, C. First Axl inhibitor enters clinical trials Nat. Biotechnol. 2013, 31, 775-776 10.1038/nbt0913-775a
16. Verma, A.; Warner, S. L.; Vankayalapati, H.; Bearss, D. J.; Sharma, S. Targeting Axl and Mer kinases in cancer Mol. Cancer Ther. 2011, 10, 1763-1773 10.1158/1535-7163.MCT-11-0116
17. Wu, X.; Liu, X.; Koul, S.; Lee, C. Y.; Zhang, Z.; Halmos, B. AXL kinase as a novel target for cancer therapy Oncotarget 2014, 5, 9546-9563 10.18632/oncotarget.2542
18. Feneyrolles, C.; Spenlinhauer, A.; Guiet, L.; Fauvel, B.; Daydé-Cazals, B.; Warnault, P.; Chevé, G.; Yasri, A. Axl kinase as a key target for oncology: focus on small molecule inhibitors Mol. Cancer Ther. 2014, 13, 2141-2148 10.1158/1535-7163.MCT-13-1083
19. Graham, D. K.; DeRyckere, D.; Davies, K. D.; Earp, H. S. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer Nat. Rev. Cancer 2014, 14, 769-785 10.1038/nrc3847
20. Caberoy, N. B.; Zhou, Y.; Li, W. Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis EMBO J. 2010, 29, 3898-3910 10.1038/emboj.2010.265
21. Caberoy, N. B.; Alvarado, G.; Bigcas, J.-L.; Li, W. Galectin-3 is a new MerTK-specific eat-me signal J. Cell. Physiol. 2012, 227, 401-407 10.1002/jcp.22955
22. Heiring, C.; Dahlback, B.; Muller, Y. A. Ligand recognition and homophilic interactions in Tyro3: structural insights into the Axl/Tyro3 receptor tyrosine kinase family J. Biol. Chem. 2004, 279, 6952-6958 10.1074/jbc.M311750200
23. Konishi, A.; Aizawa, T.; Mohan, A.; Korshunov, V. A.; Berk, B. C. Hydrogen peroxide activates the Gas6-Axl pathway in vascular smooth muscle cells J. Biol. Chem. 2004, 279, 28766-28770 10.1074/jbc.M401977200
24. Lemke, G.; Rothlin, C. V. Immunobiology of the TAM receptors Nat. Rev. Immunol. 2008, 8, 327-336 10.1038/nri2303
25. Sinha, S.; Boysen, J.; Nelson, M.; Secreto, C.; Warner, S. L.; Bearss, D. J.; Lesnick, C.; Shanafelt, T. D.; Kay, N. E.; Ghosh, A. K. Targeted Axl inhibition primes Chronic Lymphocytic Leukemia B cells to apoptosis and shows synergistic/additive effects in combination with BTK inhibitors Clin. Cancer Res. 2015, 21, 2115-2126 10.1158/1078-0432.CCR-14-1892
26. Ruan, G. X.; Kazlauskas, A. Axl is essential for VEGF-A-dependent activation of PI3K/Akt EMBO J. 2012, 31, 1692-1703 10.1038/emboj.2012.21
27. Bellosta, P.; Costa, M.; Lin, D. A.; Basilico, C. The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding Mol. Cell. Biol. 1995, 15, 614-625 10.1128/MCB.15.2.614
28. Hankins, H. M.; Baldridge, R. D.; Xu, P.; Graham, T. R. Role of flippases, scramblases and transfer proteins in phosphatidylserine subcellular distribution Traffic 2015, 16, 35-47 10.1111/tra.12233
29. Stenhoff, J.; Dahlback, B.; Hafizi, S. Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts Biochem. Biophys. Res. Commun. 2004, 319, 871-878 10.1016/j.bbrc.2004.05.070
30. Vazquez-Martin, A.; Cufí, S.; Oliveras-Ferraros, C.; Torres-Garcia, V. Z.; Corominas-Faja, B.; Cuyàs, E.; Bonavia, R.; Visa, J.; Martin-Castillo, B.; Barrajón-Catalán, E.; Micol, V.; Bosch-Barrera, J.; Menendez, J. A. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations Sci. Rep. 2013, 3, 2560 10.1038/srep02560
31. Salian-Mehta, S.; Xu, M.; Wierman, M. E. AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival Mol. Cell. Endocrinol. 2013, 374, 92-100 10.1016/j.mce.2013.04.018
32. Rothlin, C. V.; Ghosh, S.; Zuniga, E. I.; Oldstone, M. B. A.; Lemke, G. TAM receptors are pleiotropic inhibitors of the innate immune response Cell 2007, 131, 1124-1136 10.1016/j.cell.2007.10.034
33. Mudduluru, G.; Allgayer, H. The human receptor tyrosine kinase Axl gene-promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation Biosci. Rep. 2008, 28, 161-176 10.1042/BSR20080046
34. Mudduluru, G.; Ceppi, P.; Kumarswamy, R.; Scagliotti, G. V.; Papotti, M.; Allgayer, H. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer Oncogene 2011, 30, 2888-2899 10.1038/onc.2011.13
35. Zhang, Z. F.; Lee, J. C.; Lin, L. P.; Olivas, V.; Au, V.; LaFramboise, T.; Abdel-Rahman, M.; Wang, X. Q.; Levine, A. D.; Rho, J. K.; Choi, Y. J.; Choi, C. M.; Kim, S. W.; Jang, S. J.; Park, Y. S.; Kim, W. S.; Lee, D. H.; Lee, J. S.; Miller, V. A.; Arcila, M.; Ladanyi, M.; Moonsamy, P.; Sawyers, C.; Boggon, T. J.; Ma, P. C.; Costa, C.; Taron, M.; Rosell, R.; Halmos, B.; Bivona, T. G. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Nat. Genet. 2012, 44, 852-860 10.1038/ng.2330
36. Rikova, K.; Guo, A.; Zeng, Q.; Possemato, A.; Yu, J.; Haack, H.; Nardone, J.; Lee, K.; Reeves, C.; Li, Y.; Hu, Y.; Tan, Z.; Stokes, M.; Sullivan, L.; Mitchell, J.; Wetzel, R.; Macneill, J.; Ren, J. M.; Yuan, J.; Bakalarski, C. E.; Villen, J.; Kornhauser, J. M.; Smith, B.; Li, D.; Zhou, X.; Gygi, S. P.; Gu, T. L.; Polakiewicz, R. D.; Rush, J.; Comb, M. J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 2007, 131, 1190-1203 10.1016/j.cell.2007.11.025
37. Shieh, Y. S.; Lai, C. Y.; Kao, Y. R.; Shiah, S. G.; Chu, Y. W.; Lee, H. S.; Wu, C. W. Expression of axl in lung adenocarcinoma and correlation with tumor progression Neoplasia 2005, 7, 1058-1064 10.1593/neo.05640
38. Li, Y.; Ye, X.; Tan, C.; Hongo, J. A.; Zha, J.; Liu, J.; Kallop, D.; Ludlam, M. J.; Pei, L. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis Oncogene 2009, 28, 3442-3455 10.1038/onc.2009.212
39. Berclaz, G.; Altermatt, H. J.; Rohrbach, V.; Kieffer, I.; Dreher, E.; Andres, A. C. Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast Ann. Oncol. 2001, 12, 819-824 10.1023/A:1011126330233
40. Meric, F.; Lee, W. P.; Sahin, A.; Zhang, H.; Kung, H. J.; Hung, M. C. Expression profile of tyrosine kinases in breast cancer Clin. Cancer Res. 2002, 8, 361-367
41. Bose, R.; Molina, H.; Patterson, A. S.; Bitok, J. K.; Periaswamy, B.; Bader, J. S.; Pandey, A.; Cole, P. A. Phosphoproteomic analysis of Her2/neu signaling and inhibition Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 9773-9778 10.1073/pnas.0603948103
42. Holland, S. J.; Powell, M. J.; Franci, C.; Chan, E. W.; Friera, A. M.; Atchison, R. E.; McLaughlin, J.; Swift, S. E.; Pali, E. S.; Yam, G.; Wong, S.; Lasaga, J.; Shen, M. R.; Yu, S.; Xu, W.; Hitoshi, Y.; Bogenberger, J.; Nör, J. E.; Payan, D. G.; Lorens, J. B. Multiple roles for the receptor tyrosine kinase axl in tumor formation Cancer Res. 2005, 65, 9294-9303 10.1158/0008-5472.CAN-05-0993
43. Gjerdrum, C.; Tiron, C.; Høiby, T.; Stefansson, I.; Haugen, H.; Sandal, T.; Collett, K.; Li, S.; McCormack, E.; Gjertsen, B. T.; Micklem, D. R.; Akslen, L. A.; Glackin, C.; Lorens, J. B. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 1124-1149 10.1073/pnas.0909333107
44. Liu, L.; Greger, J.; Shi, H.; Liu, Y.; Greshock, J.; Annan, R.; Halsey, W.; Sathe, G. M.; Martin, A. M.; Gilmer, T. M. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL Cancer Res. 2009, 69, 6871-6878 10.1158/0008-5472.CAN-08-4490
45. Vajkoczy, P.; Knyazev, P.; Kunkel, A.; Capelle, H. H.; Behrndt, S.; von Tengg-Kobligk, H.; Kiessling, F.; Eichelsbacher, U.; Essig, M.; Read, T. A.; Erber, R.; Ullrich, A. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 5799-5804 10.1073/pnas.0510923103
46. Keating, A. K.; Kim, G. K.; Jones, A. E.; Donson, A. M.; Ware, K.; Mulcahy, J. M.; Salzberg, D. B.; Foreman, N. K.; Liang, X.; Thorburn, A.; Graham, D. K. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity Mol. Cancer Ther. 2010, 9, 1298-1307 10.1158/1535-7163.MCT-09-0707
47. Sainaghi, P. P.; Castello, L.; Bergamasco, L.; Galletti, M.; Bellosta, P.; Avanzi, G. C. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor J. Cell. Physiol. 2005, 204, 36-44 10.1002/jcp.20265
48. Ben-Batalla, I.; Schultze, A.; Wroblewski, M.; Erdmann, R.; Heuser, M.; Waizenegger, J. S.; Riecken, K.; Binder, M.; Schewe, D.; Sawall, S.; Witzke, V.; Cubas-Cordova, M.; Janning, M.; Wellbrock, J.; Fehse, B.; Hagel, C.; Krauter, J.; Ganser, A.; Lorens, J. B.; Fiedler, W.; Carmeliet, P.; Pantel, K.; Bokemeyer, C.; Loges, S. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma Blood 2013, 122, 2443-2452 10.1182/blood-2013-03-491431
49. Hart, C. D.; De Boer, R. H. Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer OncoTargets Ther. 2013, 6, 1-7 10.2147/OTT.S27671
50. Lee, H. J.; Jeng, Y. M.; Chen, Y. L.; Chung, L.; Yuan, R. H. Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma Carcinogenesis 2014, 35, 769-775 10.1093/carcin/bgt372
51. Eder, J. P.; Shapiro, G. I.; Appleman, L. J.; Zhu, A. X.; Miles, D.; Keer, H.; Cancilla, B.; Chu, F.; Hitchcock-Bryan, S.; Sherman, L.; McCallum, S.; Heath, E. I.; Boerner, S. A.; LoRusso, P. M. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2 Clin. Cancer Res. 2010, 16, 3507-3516 10.1158/1078-0432.CCR-10-0574
52. Schroeder, G. M.; An, Y.; Cai, Z. W.; Chen, X. T.; Clark, C.; Cornelius, L. A.; Dai, J.; Gullo-Brown, J.; Gupta, A.; Henley, B.; Hunt, J. T.; Jeyaseelan, R.; Kamath, A.; Kim, K.; Lippy, J.; Lombardo, L. J.; Manne, V.; Oppenheimer, S.; Sack, J. S.; Schmidt, R. J.; Shen, G.; Stefanski, K.; Tokarski, J. S.; Trainor, G. L.; Wautlet, B. S.; Wei, D.; Williams, D. K.; Zhang, Y.; Zhang, Y.; Fargnoli, J.; Borzilleri, R. M. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily J. Med. Chem. 2009, 52, 1251-1254 10.1021/jm801586s
53. Holland, S. J.; Pan, A.; Franci, C.; Hu, Y.; Chang, B.; Li, W.; Duan, M.; Torneros, A.; Yu, J.; Heckrodt, T. J.; Zhang, J.; Ding, P.; Apatira, A.; Chua, J.; Brandt, R.; Pine, P.; Goff, D.; Singh, R.; Payan, D. G.; Hitoshi, Y. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer Cancer Res. 2010, 70, 1544-1554 10.1158/0008-5472.CAN-09-2997
54. Zhao, Z.; Wu, H.; Wang, L.; Liu, Y.; Knapp, S.; Liu, Q.; Gray, N. S. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chem. Biol. 2014, 9, 1230-1241 10.1021/cb500129t
55. Qian, F.; Engst, S.; Yamaguchi, K.; Yu, P.; Won, K. A.; Mock, L.; Lou, T.; Tan, J.; Li, C.; Tam, D.; Lougheed, J.; Yakes, F. M.; Bentzien, F.; Xu, W.; Zaks, T.; Wooster, R.; Greshock, J.; Joly, A. H. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases Cancer Res. 2009, 69, 8009-8016 10.1158/0008-5472.CAN-08-4889
56. ClinicalTrials.gov (accessed Sep 30, 2015).
57. Yakes, F. M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, F.; Bentzien, F.; Cancilla, B.; Orf, J.; You, A.; Laird, A. D.; Engst, S.; Lee, L.; Lesch, J.; Chou, Y. C.; Joly, A. H. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol. Cancer Ther. 2011, 10, 2298-2308 10.1158/1535-7163.MCT-11-0264
58. Choueiri, T. K.; Escudier, B.; Powles, T.; Mainwaring, P. N.; Rini, B. I.; Donskov, F.; Hammers, H.; Hutson, T. E.; Lee, J. L.; Peltola, K.; Roth, B. J.; Bjarnason, G. A.; Géczi, L.; Keam, B.; Maroto, P.; Heng, D. Y.; Schmidinger, M.; Kantoff, P. W.; Borgman-Hagey, A.; Hessel, C.; Scheffold, C.; Schwab, G. M.; Tannir, N. M.; Motzer, R. J. Cabozantinib versus everolimus in advanced renal-cell carcinoma N. Engl. J. Med. 2015, 373, 1814 10.1056/NEJMoa1510016
59. Yan, S. B.; Peek, V. L.; Ajamie, R.; Buchanan, S. G.; Graff, J. R.; Heidler, S. A.; Hui, Y. H.; Huss, K. L.; Konicek, B. W.; Manro, J. R.; Shih, C.; Stewart, J. A.; Stewart, T. R.; Stout, S. L.; Uhlik, M. T.; Um, S. L.; Wang, Y.; Wu, W.; Yan, L.; Yang, W. J.; Zhong, B.; Walgren, R. A. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models Invest. New Drugs 2013, 31, 833-844 10.1007/s10637-012-9912-9
60. Bonfils, C.; Beaulieu, N.; Fournel, M.; Ste-Croix, H.; Besterman, J. M.; Maroun, C. R. The combination of MGCD265, a MET/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis Cancer Res. 2012, 72, 1790 10.1158/1538-7445.AM2012-1790
61. Rho, J. K.; Choi, Y. J.; Kim, S. Y.; Kim, T. W.; Choi, E. K.; Yoon, S. J.; Park, B. M.; Park, E.; Bae, J. H.; Choi, C. M.; Lee, J. C. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation Cancer Res. 2014, 74, 253-262 10.1158/0008-5472.CAN-13-1103
62. Paolino, M.; Choidas, A.; Wallner, S.; Pranjic, B.; Uribesalgo, I.; Loeser, S.; Jamieson, A. M.; Langdon, W. Y.; Ikeda, F.; Fededa, J. P.; Cronin, S. J.; Nitsch, R.; Schultz-Fademrecht, C.; Eickhoff, J.; Menninger, S.; Unger, A.; Torka, R.; Gruber, T.; Hinterleitner, R.; Baier, G.; Wolf, D.; Ullrich, A.; Klebl, B. M.; Penninger, J. M. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells Nature 2014, 507, 508-512 10.1038/nature12998
63. Sholl, L. Evaluation of the MET/Axl Receptor Tyrosine Kinase (RTK) Inhibitor MGCD265 in a Patient with Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring AXL Amplification. Presented at the IASLC 16th World Conference on Lung Cancer, Denver, CO, 2015; 3611.
64. Messoussi, A.; Peyronnet, L.; Feneyrolles, C.; Cheve, G.; Bougrin, K.; Yasri, A. Structural elucidation of the DFG-Asp in and DFG-Asp out states of TAM kinases and insight into the selectivity of their inhibitors Molecules 2014, 19, 16223-16239 10.3390/molecules191016223
65. Remsing Rix, L. L.; Rix, U.; Colinge, J.; Hantschel, O.; Bennett, K. L.; Stranzl, T.; Müller, A.; Baumgartner, C.; Valent, P.; Augustin, M.; Till, J. H.; Superti-Furga, G. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells Leukemia 2009, 23, 477-485 10.1038/leu.2008.334
66. Zhang, Y. X.; Knyazev, P. G.; Cheburkin, Y. V.; Sharma, K.; Knyazev, Y. P.; Orfi, L.; Szabadkai, I.; Daub, H.; Kéri, G.; Ullrich, A. AXL is a potential target for therapeutic intervention in breast cancer progression Cancer Res. 2008, 68, 1905-1915 10.1158/0008-5472.CAN-07-2661
67. Wu, P.; Nielsen, T. E.; Clausen, M. H. FDA-approved small-molecule kinase inhibitors Trends Pharmacol. Sci. 2015, 36, 422-439 10.1016/j.tips.2015.04.005
68. Mori, M.; Kaneko, N.; Ueno, Y.; Tanaka, R.; Cho, K.; Saito, R.; Kondoh, Y.; Shimada, I.; Kuromitsu, S. ASP2215, a novel FLT3/AXL inhibitor: preclinical evaluation in acute myeloid leukemia (AML) J. Clin. Oncol. 2014, 32, 7070
69. Annesley, C. E.; Brown, P. The biology and targeting of FLT3 in pediatric leukemia Front. Oncol. 2014, 4, 263 10.3389/fonc.2014.00263
70. Wang, X.; Saso, H.; Iwamoto, T.; Xia, W.; Gong, Y.; Pusztai, L.; Woodward, W. A.; Reuben, J. M.; Warner, S. L.; Bearss, D. J.; Hortobagyi, G. N.; Hung, M. C.; Ueno, N. T. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase Cancer Res. 2013, 73, 6516-6525 10.1158/0008-5472.CAN-13-0967
71. Mollard, A.; Warner, S. L.; Call, L. T.; Wade, M. L.; Bearss, J. J.; Verma, A.; Sharma, S.; Vankayalapati, H.; Bearss, D. J. Design, synthesis and biological evaluation of a series of novel AXL kinase inhibitors ACS Med. Chem. Lett. 2011, 2, 907-912 10.1021/ml200198x
72. Cui, J. J.; Tran-Dubé, M.; Shen, H.; Nambu, M.; Kung, P. P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R. S.; Edwards, M. P. Structure based drug design of Crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 2011, 54, 6342-6363 10.1021/jm2007613
73. McDermott, U.; Iafrate, A. J.; Gray, N. S.; Shioda, T.; Classon, M.; Maheswaran, S.; Zhou, W.; Choi, H. G.; Smith, S. L.; Dowell, L.; Ulkus, L. E.; Kuhlmann, G.; Greninger, P.; Christensen, J. G.; Haber, D. A.; Settleman, J. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors Cancer Res. 2008, 68, 3389-3395 10.1158/0008-5472.CAN-07-6186
74. Zou, H. Y.; Li, Q.; Lee, J. H.; Arango, M. E.; McDonnell, S. R.; Yamazaki, S.; Koudriakova, T. B.; Alton, G.; Cui, J. J.; Kung, P. P.; Nambu, M. D.; Los, G.; Bender, S. L.; Mroczkowski, B.; Christensen, J. G. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms Cancer Res. 2007, 67, 4408-4417 10.1158/0008-5472.CAN-06-4443
75. Kwak, E. L.; Bang, Y. J.; Camidge, D. R.; Shaw, A. T.; Solomon, B.; Maki, R. G.; Ou, S. H.; Dezube, B. J.; Jänne, P. A.; Costa, D. B.; Varella-Garcia, M.; Kim, W. H.; Lynch, T. J.; Fidias, P.; Stubbs, H.; Engelman, J. A.; Sequist, L. V.; Tan, W.; Gandhi, L.; Mino-Kenudson, M.; Wei, G. C.; Shreeve, S. M.; Ratain, M. J.; Settleman, J.; Christensen, J. G.; Haber, D. A.; Wilner, K.; Salgia, R.; Shapiro, G. I.; Clark, J. W.; Iafrate, A. J. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N. Engl. J. Med. 2010, 363, 1693-1703 10.1056/NEJMoa1006448
76. Shaw, A. T.; Kim, D. W.; Nakagawa, K.; Seto, T.; Crinó, L.; Ahn, M. J.; De Pas, T.; Besse, B.; Solomon, B. J.; Blackhall, F.; Wu, Y. L.; Thomas, M.; O'Byrne, K. J.; Moro-Sibilot, D.; Camidge, D. R.; Mok, T.; Hirsh, V.; Riely, G. J.; Iyer, S.; Tassell, V.; Polli, A.; Wilner, K. D.; Jänne, P. A. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N. Engl. J. Med. 2013, 368, 2385-2394 10.1056/NEJMoa1214886
77. Sahu, A.; Prabhash, K.; Noronha, V.; Joshi, A.; Desai, S. Crizotinib: A comprehensive review South Asian J. Cancer 2013, 2, 91-97 10.4103/2278-330X.110506
78. Costa, D. B.; Shaw, A. T.; Ou, S. H.; Solomon, B. J.; Riely, G. J.; Ahn, M. J.; Zhou, C.; Shreeve, S. M.; Selaru, P.; Polli, A.; Schnell, P.; Wilner, K. D.; Wiltshire, R.; Camidge, D. R.; Crinò, L. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases J. Clin. Oncol. 2015, 33, 1881 10.1200/JCO.2014.59.0539
79. Mahadevan, D.; Cooke, L.; Riley, C.; Swart, R.; Simons, B.; Della Croce, K.; Wisner, L.; Iorio, M.; Shakalya, K.; Garewal, H.; Nagle, R.; Bearss, D. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors Oncogene 2007, 26, 3909-3919 10.1038/sj.onc.1210173
80. Asiedu, M. K.; Beauchamp-Perez, F. D.; Ingle, J. N.; Behrens, M. D.; Radisky, D. C.; Knutson, K. L. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells Oncogene 2014, 33, 1316-1324 10.1038/onc.2013.57
81. Choy, G.; Joshi-Hangal, R.; Oganesian, A.; Fine, G.; Rasmussen, S.; Collier, J.; Kissling, J.; Sahai, A.; Azab, M.; Redkar, S. Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers Cancer Chemother. Pharmacol. 2012, 70, 183-190 10.1007/s00280-012-1821-2
82. Zhang, W.; DeRyckere, D.; Hunter, D.; Liu, J.; Stashko, M. A.; Minson, K. A.; Cummings, C. T.; Lee, M.; Glaros, T. G.; Newton, D. L.; Sather, S.; Zhang, D.; Kireev, D.; Janzen, W. P.; Earp, H. S.; Graham, D. K.; Frye, S. V.; Wang, X. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor J. Med. Chem. 2014, 57, 7031-7041 10.1021/jm500749d
83. Liu, J.; Zhang, W.; Stashko, M. A.; Deryckere, D.; Cummings, C. T.; Hunter, D.; Yang, C.; Jayakody, C. N.; Cheng, N.; Simpson, C.; Norris-Drouin, J.; Sather, S.; Kireev, D.; Janzen, W. P.; Earp, H. S.; Graham, D. K.; Frye, S. V.; Wang, X. UNC1062, a new and potent Mer inhibitor Eur. J. Med. Chem. 2013, 65, 83-93 10.1016/j.ejmech.2013.03.035
84. Schlegel, J.; Sambade, M. J.; Sather, S.; Moschos, S. J.; Tan, A. C.; Winges, A.; DeRyckere, D.; Carson, C. C.; Trembath, D. G.; Tentler, J. J.; Eckhardt, S. G.; Kuan, P. F.; Hamilton, R. L.; Duncan, L. M.; Miller, C. R.; Nikolaishvili-Feinberg, N.; Midkiff, B. R.; Liu, J.; Zhang, W.; Yang, C.; Wang, X.; Frye, S. V.; Earp, H. S.; Shields, J. M.; Graham, D. K. MERTK receptor tyrosine kinase is a therapeutic target in melanoma J. Clin. Invest. 2013, 123, 2257-2267 10.1172/JCI67816
85. Burbridge, M. F.; Bossard, C. J.; Saunier, C.; Fejes, I.; Bruno, A.; Léonce, S.; Ferry, G.; Da Violante, G.; Bouzom, F.; Cattan, V.; Jacquet-Bescond, A.; Comoglio, P. M.; Lockhart, B. P.; Boutin, J. A.; Cordi, A.; Ortuno, J. C.; Pierré, A.; Hickman, J. A.; Cruzalegui, F. H.; Depil, S. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab Mol. Cancer Ther. 2013, 12, 1749-1762 10.1158/1535-7163.MCT-13-0075
86. Blumenthal, G. M.; Cortazar, P.; Zhang, J.; Tang, S.; Sridhara, R.; Murgo, A.; Justice, R.; Pazdur, R. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors Oncologist 2012, 17, 1108-1113 10.1634/theoncologist.2012-0044
87. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-132 10.1038/nbt1358
88. Bhide, R. S.; Cai, Z. W.; Zhang, Y. Z.; Qian, L.; Wei, D.; Barbosa, S.; Lombardo, L. J.; Borzilleri, R. M.; Zheng, X.; Wu, L. I.; Barrish, J. C.; Kim, S. H.; Leavitt, K.; Mathur, A.; Leith, L.; Chao, S.; Wautlet, B.; Mortillo, S.; Jeyaseelan, R., Sr.; Kukral, D.; Hunt, J. T.; Kamath, A.; Fura, A.; Vyas, V.; Marathe, P.; D'Arienzo, C.; Derbin, G.; Fargnoli, J. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-X+36. 5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor J. Med. Chem. 2006, 49, 2143-2146 10.1021/jm051106d
89. Schroeder, G. M.; Chen, X. T.; Williams, D. K.; Nirschl, D. S.; Cai, Z. W.; Wei, D.; Tokarski, J. S.; An, Y.; Sack, J.; Chen, Z.; Huynh, T.; Vaccaro, W.; Poss, M.; Wautlet, B.; Gullo-Brown, J.; Kellar, K.; Manne, V.; Hunt, J. T.; Wong, T. W.; Lombardo, L. J.; Fargnoli, J.; Borzilleri, R. M. Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase Bioorg. Med. Chem. Lett. 2008, 18, 1945-1951 10.1016/j.bmcl.2008.01.121
90. Cai, Z. W.; Wei, D.; Schroeder, G. M.; Cornelius, L. A.; Kim, K.; Chen, X. T.; Schmidt, R. J.; Williams, D. K.; Tokarski, J. S.; An, Y.; Sack, J. S.; Manne, V.; Kamath, A.; Zhang, Y.; Marathe, P.; Hunt, J. T.; Lombardo, L. J.; Fargnoli, J.; Borzilleri, R. M. Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 3224-3229 10.1016/j.bmcl.2008.04.047
91. Kim, K. S.; Zhang, L.; Schmidt, R.; Cai, Z. W.; Wei, D.; Williams, D. K.; Lombardo, L. J.; Trainor, G. L.; Xie, D.; Zhang, Y.; An, Y.; Sack, J. S.; Tokarski, J. S.; Darienzo, C.; Kamath, A.; Marathe, P.; Zhang, Y.; Lippy, J.; Jeyaseelan, R., Sr.; Wautlet, B.; Henley, B.; Gullo-Brown, J.; Manne, V.; Hunt, J. T.; Fargnoli, J.; Borzilleri, R. M. Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities J. Med. Chem. 2008, 51, 5330-5341 10.1021/jm800476q
92. Graham, D. K.; Salzberg, D. B.; Kurtzberg, J.; Sather, S.; Matsushima, G. K.; Keating, A. K.; Liang, X.; Lovell, M. A.; Williams, S. A.; Dawson, T. L.; Schell, M. J.; Anwar, A. A.; Snodgrass, H. R.; Earp, H. S. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia Clin. Cancer Res. 2006, 12, 2662-2669 10.1158/1078-0432.CCR-05-2208
93. Gray, N. S.; Wodicka, L.; Thunnissen, A. M.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S. H.; Lockhart, D. J.; Schultz, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors Science 1998, 281, 533-538 10.1126/science.281.5376.533
94. Huang, X.; Finerty, P., Jr.; Walker, J. R.; Butler-Cole, C.; Vedadi, M.; Schapira, M.; Parker, S. A.; Turk, B. E.; Thompson, D. A.; Dhe-Paganon, S. Structural insights into the inhibited states of the Mer receptor tyrosine kinase J. Struct. Biol. 2009, 165, 88-96 10.1016/j.jsb.2008.10.003
95. Liu, J.; Yang, C.; Simpson, C.; Deryckere, D.; Van Deusen, A.; Miley, M. J.; Kireev, D.; Norris-Drouin, J.; Sather, S.; Hunter, D.; Korboukh, V. K.; Patel, H. S.; Janzen, W. P.; Machius, M.; Johnson, G. L.; Earp, H. S.; Graham, D. K.; Frye, S. V.; Wang, X. Discovery of novel small molecule Mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia ACS Med. Chem. Lett. 2012, 3, 129-134 10.1021/ml200239k
96. Zhang, W.; Zhang, D.; Stashko, M. A.; DeRyckere, D.; Hunter, D.; Kireev, D.; Miley, M. J.; Cummings, C.; Lee, M.; Norris-Drouin, J.; Stewart, W. M.; Sather, S.; Zhou, Y.; Kirkpatrick, G.; Machius, M.; Janzen, W. P.; Earp, H. S.; Graham, D. K.; Frye, S. V.; Wang, X. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors J. Med. Chem. 2013, 56, 9683-9692 10.1021/jm401387j
97. Zhang, W.; McIver, A. L.; Stashko, M. A.; DeRyckere, D.; Branchford, B. R.; Hunter, D.; Kireev, D.; Miley, M. J.; Norris-Drouin, J.; Stewart, W. M.; Lee, M.; Sather, S.; Zhou, Y.; Di Paola, J. A.; Machius, M.; Janzen, W. P.; Earp, H. S.; Graham, D. K.; Frye, S. V.; Wang, X. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis J. Med. Chem. 2013, 56, 9693-9700 10.1021/jm4013888
98. Singh, R.; Heckrodt, T. J.; Holland, S. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors. Int. Patent WO 2010/005876 A2, 2010.
99. Wnuk-Lipinska, K.; Tiron, C.; Gausdal, G.; Sandal, T.; Frink, R.; Hinz, S.; Hellesøy, M.; Ahmed, L.; Haugen, H.; Liang, X.; Blø, M.; Micklem, D.; Yule, M.; Minna, J.; Zhou, L.; Brekken, R.; Lorens, J. Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies Cancer Res. 2014, 74, 1747 10.1158/1538-7445.AM2014-1747
100. Goff, D.; Zhang, J.; Singh, R.; Holland, S.; Yu, J.; Heckrodt, T. J.; Ding, P.; Litvak, J. Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors. Int. Patent US 8,741,898 B2, 2014.
101. Ding, P.; Goff, D.; Zhang, J.; Singh, R.; Holland, S.; Yu, J.; Heckrodt, T. J.; Litvak, J. N3-Heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as axl inhibitors. Int. Patent US 8,796,259 B2, 2014.
102. Robinson, D. R.; Wu, Y. M.; Lin, S. F. The protein tyrosine kinase family of the human genome Oncogene 2000, 19, 5548-5557 10.1038/sj.onc.1203957
103. Suárez, R. M.; Chevot, F.; Cavagnino, A.; Saettel, N.; Radvanyi, F.; Piguel, S.; Bernard-Pierrot, I.; Stoven, V.; Legraverend, M. Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation Eur. J. Med. Chem. 2013, 61, 2-25 10.1016/j.ejmech.2012.06.005
104. Cui, J. J. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress J. Med. Chem. 2014, 57, 4427-4453 10.1021/jm401427c
105. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29, 1046-1051 10.1038/nbt.1990
106. Elisei, R.; Schlumberger, M. J.; Müller, S. P.; Schöffski, P.; Brose, M. S.; Shah, M. H.; Licitra, L.; Jarzab, B.; Medvedev, V.; Kreissl, M. C.; Niederle, B.; Cohen, E. E.; Wirth, L. J.; Ali, H.; Hessel, C.; Yaron, Y.; Ball, D.; Nelkin, B.; Sherman, S. I. Cabozantinib in progressive medullary thyroid cancer J. Clin. Oncol. 2013, 31, 3639-3646 10.1200/JCO.2012.48.4659
107. De Smet, F.; Christopoulos, A.; Carmeliet, P. Allosteric targeting of receptor tyrosine kinases Nat. Biotechnol. 2014, 32, 1113-1120 10.1038/nbt.3028
108. Carmi, C.; Mor, M.; Petronini, P. G.; Alfieri, R. R. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer Biochem. Pharmacol. 2012, 84, 1388-1399 10.1016/j.bcp.2012.07.031
109. Lu, Q. X.; Lemke, G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family Science 2001, 293, 306-311 10.1126/science.1061663
110. Bosurgi, L.; Bernink, J. H.; Delgado Cuevas, V.; Gagliani, N.; Joannas, L.; Schmid, E. T.; Booth, C. J.; Ghosh, S.; Rothlin, C. V. Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 13091-13096 10.1073/pnas.1302507110
111. Schmidt, T.; Ben-Batalla, I.; Schultze, A.; Loges, S. Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands Cell. Mol. Life Sci. 2012, 69, 1391-1414 10.1007/s00018-011-0863-7
112. McDermott, U.; Settleman, J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology J. Clin. Oncol. 2009, 27, 5650-5659 10.1200/JCO.2009.22.9054
113. Carragher, N. O.; Unciti-Broceta, A.; Cameron, D. A. Advancing cancer drug discovery towards more agile development of targeted combination therapies Future Med. Chem. 2012, 4, 87-105 10.4155/fmc.11.169
114. Holohan, C.; Van Schaeybroeck, S.; Longley, D. B.; Johnston, P. G. Cancer drug resistance: an evolving paradigm Nat. Rev. Cancer 2013, 13, 714-726 10.1038/nrc3599
115. Elkabets, M.; Pazarentzos, E.; Juric, D.; Sheng, Q.; Pelossof, R. A.; Brook, S.; Benzaken, A. O.; Rodon, J.; Morse, N.; Yan, J. J.; Liu, M.; Das, R.; Chen, Y.; Tam, A.; Wang, H.; Liang, J.; Gurski, J. M.; Kerr, D. A.; Rosell, R.; Teixidó, C.; Huang, A.; Ghossein, R. A.; Rosen, N.; Bivona, T. G.; Scaltriti, M.; Baselga, J. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas Cancer Cell 2015, 27, 533-546 10.1016/j.ccell.2015.03.010